Trials / Conditions / Gastric / Gastroesophageal Junction Adenocarcinoma

Gastric / Gastroesophageal Junction Adenocarcinoma

20 registered clinical trials studyying Gastric / Gastroesophageal Junction Adenocarcinoma — 18 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advance NCT07508956	Shanghai Zhongshan Hospital	Phase 3
Not Yet Recruiting	A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combinatio NCT07449780	Akeso	Phase 3
Not Yet Recruiting	IBI343 in Combination Therapy for Advanced Malignant Solid Tumors NCT07483554	Innovent Biologics (Suzhou) Co. Ltd.	Phase 2
Not Yet Recruiting	Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma NCT07259473	Shanghai Zhongshan Hospital	Phase 2
Not Yet Recruiting	Zanidatamab Combined With Chemotherapy as Neoadjuvant Therapy for HER2-high Expression G/GEJC NCT07273981	Xijing Hospital	Phase 2
Not Yet Recruiting	Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advance NCT07257380	Shanghai Zhongshan Hospital	Phase 2
Not Yet Recruiting	A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers NCT07233850	Shenyang Sunshine Pharmaceutical Co., LTD.	Phase 2
Not Yet Recruiting	Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Ade NCT07161453	Liaoning Cancer Hospital & Institute	Phase 4
Not Yet Recruiting	Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Ade NCT07148427	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Not Yet Recruiting	Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer NCT07127822	Peking University	Phase 2
Not Yet Recruiting	Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatm NCT07132528	Liaoning Cancer Hospital & Institute	Phase 4
Not Yet Recruiting	Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adju NCT07149181	Liaoning Cancer Hospital & Institute	Phase 4
Not Yet Recruiting	Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junct NCT07092449	Tang-Du Hospital	N/A
Not Yet Recruiting	Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Ju NCT06764251	Liaoning Cancer Hospital & Institute	Phase 2
Recruiting	A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcino NCT06415669	The First Affiliated Hospital of Xiamen University	Phase 2
Recruiting	Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonil NCT06406426	Fudan University	Phase 2
Recruiting	A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poo NCT06774222	Henan Cancer Hospital	Phase 2
Unknown	Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafol NCT06030934	Fudan University	Phase 2
Unknown	Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastri NCT05387681	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 2
Recruiting	A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advan NCT04895709	Bristol-Myers Squibb	Phase 1 / Phase 2